Pharmaceutical dronedarone composition for parenteral...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S469000

Reexamination Certificate

active

06939865

ABSTRACT:
A subject-matter of the invention is a pharmaceutical composition for parenteral administration, characterized in that it comprises: dronedarone or one of its pharmaceutically acceptable salts as active principle; a physiologically acceptable buffer solution capable of maintaining the pH of the composition between 3 and 5; a physiologically acceptable water-soluble β-cyclodextrin derivative.

REFERENCES:
patent: 5985915 (1999-11-01), Frangin et al.
Verduyn, S.C.; Vos, Ma; Leunissen, H.D.; “Evaluation of the acute electrophysiologic effects of intraveneous Dronedarone . . . ”; Journal of Cardiovascular Pharmacology, vol. 33, no. 2, 1999, pp 212-222; XP001024499, p 213, col. 2, lines 44-62.
Manning, A; Thisse, V.; Hodeige, D.; “SR33589, a new amiadarone-like antiarrhythmic agent . . . ”; Journal of Cardiovascular Pharmacology, vol. 25, no. 2, 1995, pp 252-261; XP001024497, p 253, col. 2, lines 1-18.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Pharmaceutical dronedarone composition for parenteral... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical dronedarone composition for parenteral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical dronedarone composition for parenteral... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3419858

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.